Anavex announces precision medicine results of oral blarcamesine treatment

Anavex (AVXL) Life Sciences announced the latest findings for blarcamesine, an oral small molecule for the potential treatment of early Alzheimer’s disease. The data were presented by Marwan Noel Sabbagh, MD, Professor of Neurology, and Chairman of the Anavex Scientific Advisory Board at the 2025 Alzheimer’s Association International Conference, held in Toronto. Blarcamesine-treated patients continue to accrue benefit through up to 4 years, as measured by the prespecified clinical endpoints ADAS-Cog13 and ADCS-ADL, respectively. In the intent-to-treat population, delayed-start analysis of treatment with oral blarcamesine was significant for both cognition and function, reflecting the importance of early treatment initiation. For ADAS-Cog13 a significant difference between the early-start and late-start treatment groups at Week 192 was observed. Similarly, for ADCS-ADL at Week 192 statistical significance was reached, both favoring the early-start group. Additionally, the GWAS-identified population ABCLEAR2, with a global frequency of ~71.7%, showed further improvement in both cognition, ADAS-Cog13, and function, ADCS-ADL, respectively. This clinical Precision Medicine population data demonstrates up to 84.6 Weeks of ‘time saved’ by the early-start analysis.